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Novelty statement:  
 Stimulated urine C-peptide/creatinine ratio can detect decline in beta-
cell function in the first 12 months after diagnosis of type 1 diabetes  
 In the first 6 months period after diagnosis there was poor correlation of 
the change in both stimulated serum and urine C-peptide with changes 
in metabolic measures (insulin dose adjusted HbA1c). 
 It warrants inclusion in further prospective interventional and 
observations studies in type 1 diabetes.  
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ABSTRACT 
Urine C-peptide/creatinine ratio measured after a mixed meal (MM-UCPCR) 
has been suggested as a less invasive alternative to the standard Mixed Meal 
Tolerance Test (MMTT) in assessing beta-cell function. There are limited data 
comparing these two measures soon after diagnosis of type 1 diabetes 
(T1DM), when beta-cell stress may affect insulin production.  
Aims. To determine if UCPCR is a useful tool for monitoring beta-cell function 
in new-onset T1DM. 
Methods. Data were obtained from a prospective immunomodulation study in 
people with T1DM ≤3 months from diagnosis with a standard MMTT and MM-
UCPCR carried out at 0, 3, 6, 9 and 12 months. The change in the insulin 
dose adjusted HbA1c was correlated with the change in serum/urine C-
peptide during the 12 months follow-up period.  
Results. A significant reduction of MM-UCPCR was detected within 9 months. 
Stimulated serum and urine C-peptide responses did not correlate at baseline 
or 3 months in new onset participants, but did correlate after 6, 9 and 12 
months. Neither the change in stimulated serum nor the urine C-peptide 
correlated with the change in insulin dose adjusted HbA1c in the first 6 
months, but all measures correlated significantly at 9 and 12 months. 
Conclusion. MM stimulated UCPCR is comparable to, although less sensitive 
than, stimulated serum C-peptide in monitoring beta-cell function during the 
first year from diagnosis. Since it is significantly less invasive, it warrants 
inclusion in further studies in T1DM and may represent an attractive 
alternative outcome measure in cohort studies and children.  
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INTRODUCTION 
 
With increasing focus on immunomodulation(1-4) to preserve beta-cell 
function in T1DM, early identification of responders is of particular interest.  
People with impaired beta-cell function secrete smaller quantities of C-peptide 
in response to stimuli and exhibit a delay in reaching peak C-peptide(5). 
There is evidence of accelerated beta-cell damage around the time of 
diagnosis(6, 7). After resolution of glucotoxicity(8) and given that the beta-cell 
has limited potential for proliferation in recent-onset T1DM(9), it is possible 
that there may be diminished and erratic insulin/C-peptide production early 
after diagnosis, which may stabilise later. 
Determining a reliable method to establish the efficacy of beta-cell restoration 
treatments is important. Most clinical trials use the Mixed Meal Tolerance Test 
(MMTT) as the gold standard to assess beta-cell function(10). A surrogate 
measure of beta-cell function, insulin dose adjusted HbA1c (IDAA1c) also 
correlates well with peak serum C-peptide 12 months after diagnosis(11). 
More recently, stimulated post-meal 2-hour urine C-peptide/creatinine ratio 
(UCPCR) has been proposed as an alternative and less invasive means of 
estimating beta-cell function(12). However, there are limited data comparing 
UCPCR and serum C-peptide measurements soon after diagnosis of T1DM 
and no prospective studies. Fasting UCPCR has been shown to be insensitive 
to capture changing insulin production in an immunointervention trial(13), 
however the finding that stimulated UCPCR can be used as a tool for 
monitoring beta-cell function in islet transplant patients suggests that it may 
be a useful outcome measure(14). Urine c-peptide samples are easy for 
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patients to send in samples by post, and combined with the less invasive 
nature of UCPCR testing makes it potentially very attractive as an outcome 
measure in large cohort/community studies and children.  
Here we compare serial measurements of urine and serum C-peptide in 
people with newly diagnosed T1DM over a period of 12 months during an 
intervention trial.   
 
METHODS 
 
Setting and participants 
This multi-centre, double-blinded randomised controlled intervention trial, was 
designed to assess the safety of C19-A3 proinsulin peptide administration and 
the change in stimulated C−peptide production between baseline and 12 
months after treatment in adults with new-onset T1DM. The primary outcomes 
of this study are reported elsewhere (in submission). Twenty seven adults 
with T1DM of ≤3 months duration (time from the insulin treatment start to the 
initiation of study drug ≤100 days), were recruited from June 2013 to March 
2014 from 5 UK centers. Participants were randomised into 3 groups: placebo 
(n=8, age 28.98.2 years, female:male=2:6), low-frequency treatment group 
(six 4-weekly peptide injections; n=10, age 26.65.5 years, female:male=4:6) 
and high-frequency treatment group (twelve 2-weekly peptide injections; n=9, 
age 30.05.7 years, female:male=3:6). The treatment period was 6 months 
followed by an observation period of 6 months. Participants received insulin 
injections as a part of standard clinical care. 
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The study was approved by South West 2 Research Ethics Committee 
(ClinicalTrials.gov Identifier NCT01536431, ISRCTN 66760879). All 
participants gave written informed consent. 
 
Beta-cell stimulation methods 
Ensure Plus® (Abbott Nutrition, 6ml/kg (max 360ml)) was used as a Mixed 
Meal (MM) stimulant of beta-cell production, in both the standard MMTT and 
stimulated urine C-peptide measurements. 
The standard MMTT was carried out after overnight fast as described 
before(10) at 0, 3, 6, 9 and 12 months. Serum samples for C-peptide (sCP) 
and glucose were collected at -10, 0, 15, 30, 60, 90 and 120 min. Urine 
samples were collected from the second void in the morning (before MM) and 
120 min after the MM (MM-UCPCR). All urine was collected between 0 and 
120 minutes. 
 
Urine and serum samples 
Urine samples were collected into boric acid containers (Sterilin, Thermo 
Scientific) and transported to a laboratory at ambient temperature within 72h. 
If not assayed within 72 hours of collection they were stored at -80oC for up to 
14 days until assay.  
Serum samples were stored at -20oC and sent to the lab (in dry ice) in 
batches where they were assayed.  
 
Assay methods 
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Urine C-peptide was measured, in samples diluted 1:10, by ELISA (Mercodia, 
UK). Detection limit for the C-peptide assay was 25 pmol/l with inter-assay CV 
of <5%. Urine creatinine was assayed by a colorimetric method (Jaffe 
reaction, Randox Ltd, UK). Detection limit and inter-assay CV% were 100 
umol/l and ≤5.3% respectively. Results were expressed as UCPCR 
(nmol/mmol).  
Serum C-peptide was measured by an immunochemiluminometric assay 
(Invitron, UK). Detection limit and inter-assay CV were 5pmol/l and ≤7.8% 
respectively. 
 
Statistical analysis  
Data are expressed as mean±SD. Non-normally distributed data are 
expressed as median with interquartile range. Differences were considered 
significant if p value was <0.05. GraphPad Prism version 4.0a for Macintosh 
was used for the analysis. 
The area under the curve (AUC) was calculated using the trapezoidal method 
not adjusted for the baseline C-peptide but normalised for the 120 minutes 
period of the standard MMTT using the sCP value at each time point.  
Insulin dose adjusted HbA1c (IDAA1c) was calculated according to the 
following formula: HbA1c (%) + [4 × insulin dose (units per kilogram per 24 
h)].(11) 
Non-parametric Spearman correlation was performed to correlate the AUC 
sCP during standard MMTT/stimulated UCPCR and IDAA1c (change 
comparing to baseline (Δ)). The strength of association between measures 
was assessed by correlation coefficient (r) and p value.  
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Wilcoxon signed ranked test was used to test the significance of percentage 
change in relation to the baseline value.  
 
RESULTS 
AUC sCP correlated with peak sCP during MMTT throughout the follow-up 
period (before: r=0.98; 3months: r=0.98; 6months: r=0.83, 9months: r=0.94, 
12months: r=0.97; all p<0.0001) and is used as a comparison variable to the 
urine C-peptide for the measurement of beta-cell function.  
A significant reduction of MM-UCPCR was reached at 9 months (-45.4%, 
p=0.03), whilst the reduction in AUC sCP reached significance after 3 months 
(-54.7%, p=0.008) in placebo treated participants, Table 1.  
In the pooled analysis of placebo and treatment group, the change from 
baseline in AUC sCP did not correlate with the change in the corresponding 
MM-UCPCR after 3 months (r=0.17, p=0.48). However, a significant 
correlation was achieved after 6 months (r=0.56, p=0.007), 9 months (r=0.65, 
p=0.002) and 12 months (r=0.54, p= 0.02).  
Consistently, neither the change in stimulated serum nor in urine C-peptide 
correlated with the change in IDAA1c in the first 6 months (MM-UCPCR - 
Figure 1a and b; MM-AUC sCP - Figure 1e and f). However, at 9 and 12 
months, both variables reached significant correlation with IDAA1c (MM-
UCPCR, 9 and 12 months: r=-0.60, p=0.02; r=-0.68, p=0.005, respectively, 
Figure 1c and d; MM-AUC sCP, 9 and 12 months: r=-0.64, p=0.002; r=-0.66, 
p=0.001, respectively, Figure 1g and h). 
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DISCUSSION 
 
Although stimulated UCPCR correlates well with AUC sCP in people with 
established T1DM(12), there is no information on how UCPCR performs as a 
test around the time of diagnosis or in prospective assessment of beta-cell 
function decline. The non-invasive nature of UCPCR measurement(12), 
makes it suited to large epidemiology studies. Our data in adults with new-
onset T1DM suggests that stimulated UCPCR can be used as a robust 
outcome marker to measure decline in beta-cell function over the first 12 (but 
not 6) months from diagnosis. It appears to have slightly less sensitivity to 
change than AUC sCP, potentially requiring a larger sample size, but this will 
need to be balanced against the advantages of convenience and 
acceptability.  
Both UCPCR and AUC sCP correlated poorly with a clinical measure of beta-
cell function, IDAA1c, and with each other in the first 6 months after diagnosis, 
but improved over the second half of the follow-up period. These findings are 
consistent with a report of serum analyses from the combined TrialNet studies 
in which correlation between peak serum C-peptide and IDAA1c strengthens 
as the two year follow-up of over sixty newly diagnosed participants 
progressed(15). The initial lack of correlation in the first 6 months in our cohort 
may either be specific to adults or due to limit power in the current study. 
However, Mortensen et al. observed that IDAA1c and serum C-peptide have 
comparable validity in defining partial remission of T1D not earlier than 3 
months from diagnosis(11). 
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It is possible that the insulin production is affected by the increased beta-cell 
stress reported during the first weeks after diagnosis measured by markers 
such as proinsulin/C-peptide ratio(16) and beta-cell death(17). Furthermore, it 
was observed in participants in the placebo arm of the early ciclosporin 
studies, that that the proinsulin/C-peptide ratio does not normalise until 9 
months after diagnosis(18). It is unlikely that higher beta-cell reserve 
observed at the beginning of the study had a significant influence, as another 
study in people post islet-cell transplant with higher C-peptide production 
showed clear correlation between rapidly improving beta-cell function and 
glycaemic control(19).  
The study has several limitations. It is possible that the intervention in the 
treatment group may have had a beneficial influence on C-peptide production. 
However, to overcome this, the correlation between the change in the 
measurements within the same individual (IDAA1c and C-peptide), was 
assessed. Differences in gender (20) and baseline renal function (c-peptide 
excretion) should not impact on this measure. Changes in renal function 
during the study might have an effect but were not seen.  
Our data provide promising evidence that serial measurements of stimulated 
UCPCR can detect the decline in beta-cell function after the first year from 
diagnosis, where this was not seen using fasting urine c-peptide in a larger 
study. Cross-sectional studies suggest that home post UCPCR samples 
correlate well with MMTT stimulated measures(12), and this may there 
represent an even more convenient measure for use in large scale community 
studies. Further prospective studies are required to confirm this.  
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TABLES  
Table 1. Change in MM-UCPCR (n=7) and MM-AUC sCP (n=8) in placebo treated 
MonoPepT1De participants.  
 
UCPCR 
(nmol/mmol) 
0 3 months 
6  
months 
9 
months 
12 
months 
Median 1.43 1.03 0.73 0.78 0.33 
Min 0.60 0.40 0.28 0.16 0.007 
Max 1.71 7.57 1.50 1.25 1.71 
IQR* 1.06 to 1.54 0.99 to 3.60 0.35 to 1.07 0.28 to 0.92 0.11 to 1.25 
p**  
 
 0.58 0.11 0.03 0.047 
AUC C peptide 
([nmol x min]/l) 
0 3 months 
6  
months 
9 
months 
12 
months 
Median 0.53 0.24 0.22 0.30 0.21 
Min 0.30 0.08 0.10 0.08 0.05 
Max 0.98 0.46 0.75 0.89 0.69 
IQR* 0.37 to 0.80 0.19 to 0.35 0.13 to 0.44 0.12 to 0.35 0.15 to 0.47 
p** 
 
 0.008 0.02 0.01 0.02 
*IQR – interquartile range 
** comparison to time 0 
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FIGURE LEGENDS 
Figure 1. Correlation of the change (Δ) in insulin dose adjusted HbA1c 
(IDAA1c) and stimulated serum and urine C-peptide responses collected 
during the follow up period. a-d ΔIDAA1c vs ΔMM-UCPCR: a) after 3 months 
(r=-0.24, 95% CI: -0.63 – 0.23, p=0.30, n=20); b) after 6 months (r=0.10, 95% 
CI:-0.38 – 0.54, p=0.68, n=19); c) after 9 months (r=-0.60, 95% CI: -0.85 – -
0.13, p=0.02, n=16); d) after 12 months (r=-0.68, 95% CI:-0.88 – -0.26, 
p=0.005, n=16); e-h ΔIDAA1c vs ΔMM-AUC sCP collected during the follow 
up period: e) after 3 months (r=-0.03, 95% CI: -0.43 – 0.39, p=0.89, n=24); f) 
after 6 months (r=0.18, 95% CI:-0.24 – 0.54, p=0.38, n=25); g) after 9 months 
(r=-0.64, 95% CI: -0.85 – -0.27, p=0.002, n=20); h) after 12 months (r=-0.66, 
95% CI:-0.85 – -0.31, p=0.001, n=20). 
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